TY - JOUR
T1 - Environmental exposures and systemic hypertension are risk factors for decline in lung function
AU - Miele, Catherine H.
AU - Grigsby, Matthew R.
AU - Siddharthan, Trishul
AU - Gilman, Robert H.
AU - Miranda, J. Jaime
AU - Bernabe-Ortiz, Antonio
AU - Wise, Robert A.
AU - Checkley, William
N1 - Funding Information:
This project was funded in whole with federal funds from the United States National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under contract No. HHSN268200900033C Research reported in this publication was supported by the National Heart, lung, and Blood Institute of the United States National Institutes of Health under Award Number T32HL007534. CHM was further supported by a Fogarty International Center training grant (5R25TW009340).
Funding Information:
Funding this project was funded in whole with federal funds from the United States national Heart, lung, and Blood institute, national institutes of Health, Department of Health and Human Services, under contract no. HHSn268200900033c. research reported in this publication was supported by the national Heart, lung, and Blood institute of the United States national institutes of Health under award number t32Hl007534. cHM was further supported by a Fogarty international center training grant (5r25tW009340).
Publisher Copyright:
© Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2018
Y1 - 2018
N2 - Background: Chronic lung disease is a leading contributor to the global disease burden; however, beyond tobacco smoke, we do not fully understand what risk factors contribute to lung function decline in low-income and middle-income countries. Methods: We collected sociodemographic and clinical data in a randomly selected, age-stratified, sex-stratified and site-stratified population-based sample of 3048 adults aged >35 years from four resource-poor settings in Peru. We assessed baseline and annual pre-bronchodilator and post-bronchodilator lung function over 3 years. We used linear mixed-effects models to assess biological, socioeconomic and environmental risk factors associated with accelerated lung function decline. Results: Mean±SD enrolment age was 55.4±12.5 years, 49.2% were male and mean follow-up time was 2.36 (SD 0.61) years. Mean annual pre-bronchodilator FEV, decline was 30.3 mL/year (95% ci 28.6 to 32.0) and pre-bronchodilator FVC decline was 32.2 mL/year (30.0 to 34.4). Using multivariable linear mixed-effects regression, we found that urban living, high-altitude dwelling and having hypertension accounted for 25.9% (95% Cl 15.7% to 36.1%), 21.3% (11.1% to 31.5%) and 15.7% (3.7% to 26.9%) of the overall mean annual decline in pre-bronchodilator FEV 1 /height 2 , respectively. corresponding estimates for pre-bronchodilator FVc/height 2 were 42.1% (95% ci% 29.8% to 54.4%), 36.0% (23.7% to 48.2%) and 15.8% (2.6% to 28.9%) of the overall mean annual decline, respectively. Conclusion: Urbanisation, living at high altitude and hypertension were associated with accelerated lung function decline in a population with low daily smoking prevalence.
AB - Background: Chronic lung disease is a leading contributor to the global disease burden; however, beyond tobacco smoke, we do not fully understand what risk factors contribute to lung function decline in low-income and middle-income countries. Methods: We collected sociodemographic and clinical data in a randomly selected, age-stratified, sex-stratified and site-stratified population-based sample of 3048 adults aged >35 years from four resource-poor settings in Peru. We assessed baseline and annual pre-bronchodilator and post-bronchodilator lung function over 3 years. We used linear mixed-effects models to assess biological, socioeconomic and environmental risk factors associated with accelerated lung function decline. Results: Mean±SD enrolment age was 55.4±12.5 years, 49.2% were male and mean follow-up time was 2.36 (SD 0.61) years. Mean annual pre-bronchodilator FEV, decline was 30.3 mL/year (95% ci 28.6 to 32.0) and pre-bronchodilator FVC decline was 32.2 mL/year (30.0 to 34.4). Using multivariable linear mixed-effects regression, we found that urban living, high-altitude dwelling and having hypertension accounted for 25.9% (95% Cl 15.7% to 36.1%), 21.3% (11.1% to 31.5%) and 15.7% (3.7% to 26.9%) of the overall mean annual decline in pre-bronchodilator FEV 1 /height 2 , respectively. corresponding estimates for pre-bronchodilator FVc/height 2 were 42.1% (95% ci% 29.8% to 54.4%), 36.0% (23.7% to 48.2%) and 15.8% (2.6% to 28.9%) of the overall mean annual decline, respectively. Conclusion: Urbanisation, living at high altitude and hypertension were associated with accelerated lung function decline in a population with low daily smoking prevalence.
UR - http://www.scopus.com/inward/record.url?scp=85053670535&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053670535&partnerID=8YFLogxK
U2 - 10.1136/thoraxjnl-2017-210477
DO - 10.1136/thoraxjnl-2017-210477
M3 - Article
C2 - 30061168
AN - SCOPUS:85053670535
SN - 0040-6376
VL - 73
SP - 1120
EP - 1127
JO - Thorax
JF - Thorax
IS - 12
ER -